Choose Your Country or Region

Bevacizumab (anti-VEGF)

Catalog No.A2006 Synonyms: rhuMab VEGF, Avastin

For research use only.
Not for use in humans.

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Selleck's Bevacizumab (anti-VEGF) has been cited by 17 publications

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description

Bevacizumab (anti-VEGF, Avastin) is a humanized anti-VEGF monoclonal antibody which binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments, MW:149 KD.

Targets

VEGFR2 ^[4]
()

VEGF-A ^[4]
()

VEGF ^[1]
()

In vitro

Gly88 in human VEGF is essential for binding bevacizumab and this residue also underlies the species specificity of bevacizumab binding, since a serine residue is found in mouse and rat VEGF at the corresponding position. In common with its mouse counterpart, bevacizumab binds to and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments. It does not neutralize other members of the VEGF gene family, such as VEGF-B or VEGF-C^[1].

In vivo

The terminal half-life of bevacizumab in humans is 17-21 days. Bevacizumab inhibits the growth of human tumour cell lines in nude mice, achieving a maximal inhibition at the dose of 1-2 mg per kg twice weekly. Half-maximal inhibition requires 0.1-0.5 mg per kg doses. Safety evaluation studies of bevacizumab are conducted in Macaca fascicularis (cynomolgus monkey), a species in which bevacizumab is expected to be pharmacologically active, considering the complete identity between human and cynomolgus VEGF isoforms at the protein level. Following administration of bevacizumab for four or thirteen weeks, young adult cynomolgus monkeys exhibits a physeal dysplasia characterized by a dose-related increase in hypertrophied chondrocytes and inhibition of vascular invasion of the growth plate, which is very similar to the growth-plate lesion observed in mice treated with Flt(1-3)-IgG. Other expected effects of prolonged bevacizumab administration are suppression of angiogenesis in the female reproductive tract, resulting in decreased ovarian and uterine weights, and an absence of corpora lutea. Both the growth-plate and ovarian changes are reversible with cessation of treatment. Importantly, no other treatment-related effects are observed following bevacizumab administration at doses up to 50 mg per kg^[1]. After s.c. administration, rhuMAb VEGF has a bioavailability of 69% in rats and 100% in mice and cynomolgus monkeys. It binds to primate VEGF and with lower affinity to rabbit VEGF but not to rat or mouse VEGF^[2].

Protocol (from reference)

Cell Research:	Objective: Effects of bevacizumab on VEGF-induced HUVEC proliferation Cells: Human umbilical vein endothelial cells (HUVECs) Concentrations: 0~500 ng/mL Incubation Time: 96 h Method: 50 ng/ml of rhVEGF was pre-incubated with a concentration range of bevacizumab (0-500 ng/ml) for 2 h before added to HUVACs. The plate was continuously incubated for 4 days. The proliferation of cells was determined by using Alamar Blue dye. Reference: https://www.ncbi.nlm.nih.gov/pubmed/15886877 Objective: Cell proliferation assay Cells: non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC) and renal cell carcinoma (RCC) Concentrations: 250 μg/ml Incubation Time: 24, 48, 72 or 96 hours Method: Between 2 × 10³ and 5 × 10³ cells/well (cell line/doubling time dependent) are seeded into 96 well plates and incubated overnight to adhere. Medium is then replaced by RPMI-1640 with reduced FBS and bevacizumab or VEGFA at the concentrations indicated (time point zero). After 24, 48, 72 or 96 hours in hypoxia, MTT (5 mg/ml in PBS) is added and incubated for 2 hours at 37°C. The supernatant is removed and reaction products are solubilized for 1 h in 10% HCl, 0.1% NP-40 in isopropanol. Absorbance is measured at 570 nm with a reference wavelength of 650 nm using an ELISA reader. Each experimental condition is analyzed in triplicate and results are an average of a minimum of three biological repetitions. Reference: https://www.ncbi.nlm.nih.gov/pubmed/24059699 Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)
Animal Research:	Objective: To determine the antitumor response of bevacizumab and cisplatin as single agents or in combination in xenograft models of ovarian cancer Animal Models: Nude mice were injected (i.p.) with 5×10⁶ A2780 cells Formulation: PBS Dosages: 5mg/kg Administration: i.p. Reference: https://www.ncbi.nlm.nih.gov/pubmed/19047105 Objective: To determine the pharmacokinetics of bevacizumab Animal Models: Female nude mice Formulation: -- Dosages: 9.3 mg/kg Administration: i.v. or s.c. injection Reference: https://www.ncbi.nlm.nih.gov/pubmed/9862791 Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

Cell Research:

Objective: Effects of bevacizumab on VEGF-induced HUVEC proliferation
Cells: Human umbilical vein endothelial cells (HUVECs)
Concentrations: 0~500 ng/mL
Incubation Time: 96 h
Method: 50 ng/ml of rhVEGF was pre-incubated with a concentration range of bevacizumab (0-500 ng/ml) for 2 h before added to HUVACs. The plate was continuously incubated for 4 days. The proliferation of cells was determined by using Alamar Blue dye.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/15886877

Objective: Cell proliferation assay
Cells: non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer (BC) and renal cell carcinoma (RCC)
Concentrations: 250 μg/ml
Incubation Time: 24, 48, 72 or 96 hours
Method: Between 2 × 10³ and 5 × 10³ cells/well (cell line/doubling time dependent) are seeded into 96 well plates and incubated overnight to adhere. Medium is then replaced by RPMI-1640 with reduced FBS and bevacizumab or VEGFA at the concentrations indicated (time point zero). After 24, 48, 72 or 96 hours in hypoxia, MTT (5 mg/ml in PBS) is added and incubated for 2 hours at 37°C. The supernatant is removed and reaction products are solubilized for 1 h in 10% HCl, 0.1% NP-40 in isopropanol. Absorbance is measured at 570 nm with a reference wavelength of 650 nm using an ELISA reader. Each experimental condition is analyzed in triplicate and results are an average of a minimum of three biological repetitions.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/24059699

Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

Animal Research:

Objective: To determine the antitumor response of bevacizumab and cisplatin as single agents or in combination in xenograft models of ovarian cancer
Animal Models: Nude mice were injected (i.p.) with 5×10⁶ A2780 cells
Formulation: PBS
Dosages: 5mg/kg
Administration: i.p.
Reference: https://www.ncbi.nlm.nih.gov/pubmed/19047105

Objective: To determine the pharmacokinetics of bevacizumab
Animal Models: Female nude mice
Formulation: --
Dosages: 9.3 mg/kg
Administration: i.v. or s.c. injection
Reference: https://www.ncbi.nlm.nih.gov/pubmed/9862791

Bevacizumab can apply to nude mice, various cancer cell lines and other related assays (Only for Reference)

References	[1] Ferrara N, et al. Nat Rev Drug Discov. 2004, 3(5):391-400. [2] Lin YS, et al. J Pharmacol Exp Ther. 1999, 288(1):371-8. [3] Hein M, et al. Cancer Cell Int. 2013, 13(1):94. [4] Harun Cakmak, et al. Cutan Ocul Toxicol . 2018 Jun;37(2):191-195. + Expand

References

[4] Harun Cakmak, et al. Cutan Ocul Toxicol . 2018 Jun;37(2):191-195.

+ Expand

Product Details

CAS No.	216974-75-3
Formulation	PBS buffer, pH 7.2
Isotype	Human IgG1
Source	CHO cells
Storage	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.